IMMX Penghasilan resik perusahaan Immix

Despite Immix Biopharma, Inc. (IMMX) being critically dependent on test outcomes and capital burn rates, the company focuses on developing innovative cancer immunotherapies. The company's monetary result, presented by a GURU.Markets analyst, demonstrates the current level of -0.04. The stability of this metric is complemented by a streamlined cold chain for biomaterial transportation, ensuring data integrity throughout the supply chain.

IMMX immixbio.com: Penghasilan resik ing interval 04.07.2022 - 30.10.2026

Rincian metrik keuangan lan pasar immixbio.com (IMMX)

- rega saham lan konsensus proyeksi valuasi:

Bagan rega Immix Biopharma|IMMX - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Immix Biopharma, Inc.|IMMX - Nilai Perusahaan

- data ekuitas miturut neraca:

Nilai Buku Siji Saham Immix Biopharma|IMMX - Aset Bersih Perusahaan|Koefisien Nilai Pasar marang Nilai Buku immixbio.com|IMMX - Gunggung Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Immix Biopharma, Inc.|IMMX - Utang jangka dawa marang modal|Koefisien utang jangka cendhak marang modal Immix Biopharma|IMMX - Utang perusahaan|Utang marang nilai buku Immix Biopharma, Inc.|IMMX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Immix Biopharma|Rasio cepet immixbio.com

- data bathi bisnis lan rasio investasi:

IMMX - Bathi resik perusahaan

Analisis dhasar perusahaan:IMMX, Immix

Immix Biopharma, Inc. (IMMX) focuses on developing high-tech CAR-T therapies to combat myeloma, which requires colossal R&D investments. By analyzing the company's profit metrics, an investor sees the bottom-line financial result net of all expenses, allowing for an objective assessment of the pace at which scientific achievements are capitalized and the identification of hidden risks through daily profit trends.

Pesaing utama